


HELP WANTED

FAST MIGRAINE RELIEF



THAT LASTS

*Fast onset.*

Significant migraine pain relief attained as early as 30 minutes after treatment<sup>1†</sup>

*Lasting relief.*

Demonstrated low incidence of migraine recurrence within 24 hours<sup>2‡</sup>

***No recurrence seen in 4 out of 5 patients.***

After a single 12.5 mg dose, 82% of responders had no recurrence of their migraine attack within 24 hours, in a clinical trial<sup>2‡</sup>

AXERT\* (almotriptan malate) tablets are indicated for the acute treatment of migraine with or without aura in adults. AXERT\* is not indicated for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of AXERT\* have not been established for cluster headache, which presents in older, predominately male population.

Overall, in controlled clinical trials, only three side effects occurred in more than 1% of AXERT\* patients and more frequently than in patients taking placebo: nausea (2%), dry mouth (1%) and paresthesia (1%).<sup>1</sup>

As with other triptans, AXERT\* is contraindicated in patients with history, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease, cardiac arrhythmias, uncontrolled hypertension, or in patients with other significant underlying cardiovascular disease. AXERT\* should not be administered within 24 hours of treatment with another 5-HT<sub>1</sub> agonist or an ergotamine-containing or ergot-type medication.

<sup>1</sup> AXERT 12.5 mg (n=164) compared to placebo (n=80) at 30 minutes, p=0.0485.

<sup>2</sup> Randomized, single-dose, double-blind, parallel-group multicentre study of 668 patients with acute migraine; response (n=104/183) was defined as a reduction to mild or no pain at 2 hours post-medication.

References


1. AXERT\* Product Monograph, Janssen-Ortho Inc., October 2003.

2. Dowson AJ, Massiou H, Lainez JM, et al. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. *Cephalalgia* 2002; 22(6):453-61.

**NEW**  
Pr **Axert**\*  
almotriptan malate tablets

**Fastlasting™ Relief**

 JANSSEN-ORTHO  
19 Green Belt Drive, Toronto, Ontario M3C 1L9  
www.janssen-ortho.com

Licensed from  Almiral  
\*All trademark rights used under license  
© 2004 JANSSEN-ORTHO Inc. 8005

AXJA041005A

